Biovie (BIVI) Short term Debt (2016 - 2020)

Biovie (BIVI) posted Short term Debt of $444451.0 for Q1 2020, up 1381.5% sequentially from $30000.0 in Q4 2019.

Biovie (BIVI) Short term Debt (2016 - 2020) Analysis & Trends

Biovie has reported Short term Debt for 5 years, with the latest figure at $444451.0 in Q1 2020.

Quarterly Short term Debt changed N/A year-over-year to $444451.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $444451.0 (changed N/A YoY) and the FY2017 annual result came in at $35000.0, up 250.0% from the prior year.
Short term Debt rose to $444451.0 in Q1 2020 per BIVI's latest filing, from $30000.0 in the prior quarter.
Over five years, Short term Debt peaked at $444451.0 in Q1 2020 and troughed at $8000.0 in Q3 2016.
A 5-year average of $71556.4 and a median of $17500.0 in 2016 frame the typical range for Short term Debt.
The sharpest annual moves came in 2017 and 2018: Short term Debt soared 250.0% in 2017, then surged 150.0% in 2018.
Over 5 years, Short term Debt stood at $10000.0 in 2016, then jumped by 250.0% to $35000.0 in 2017, then retreated by 28.57% to $25000.0 in 2018, then rose by 20.0% to $30000.0 in 2019, then soared by 1381.5% to $444451.0 in 2020.
According to Business Quant data, Short term Debt over the past three periods registered $444451.0, $30000.0, and $25000.0 for Q1 2020, Q4 2019, and Q1 2018 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Biovie	14.17 Mn	14.17 Mn	-

Download Data